Villar-Vesga Juan, Henao-Restrepo Julián, Voshart Daniëlle C, Aguillon David, Villegas Andrés, Castaño Diana, Arias-Londoño Julián D, Zuhorn Inge S, Ribovski Laís, Barazzuol Lara, Cardona-Gómez Gloria P, Posada-Duque Rafael
Neuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, Sede de Investigación Universitaria, University of Antioquia, Medellín, Colombia.
Institute of Biology, Faculty of Exact and Natural Sciences, University of Antioquia, Medellín, Colombia.
Front Aging Neurosci. 2020 Nov 11;12:587989. doi: 10.3389/fnagi.2020.587989. eCollection 2020.
Evidence suggests that extracellular vesicles (EVs) act as mediators and biomarkers of neurodegenerative diseases. Two distinct forms of Alzheimer disease (AD) are known: a late-onset sporadic form (SAD) and an early-onset familial form (FAD). Recently, neurovascular dysfunction and altered systemic immunological components have been linked to AD neurodegeneration. Therefore, we characterized systemic-EVs from postmortem SAD and FAD patients and evaluated their effects on neuroglial and endothelial cells. We found increase CLN-5 spots with vesicular morphology in the abluminal portion of vessels from SAD patients. Both forms of AD were associated with larger and more numerous systemic EVs. Specifically, SAD patients showed an increase in endothelial- and leukocyte-derived EVs containing mitochondria; in contrast, FAD patients showed an increase in platelet-derived EVs. We detected a differential protein composition for SAD- and FAD-EVs associated with the coagulation cascade, inflammation, and lipid-carbohydrate metabolism. Using mono- and cocultures (endothelium-astrocytes-neurons) and human cortical organoids, we showed that AD-EVs induced cytotoxicity. Both forms of AD featured decreased neuronal branches area and astrocytic hyperreactivity, but SAD-EVs led to greater endothelial detrimental effects than FAD-EVs. In addition, FAD- and SAD-EVs affected calcium dynamics in a cortical organoid model. Our findings indicate that the phenotype of systemic AD-EVs is differentially defined by the etiopathology of the disease (SAD or FAD), which results in a differential alteration of the NVU cells implied in neurodegeneration.
有证据表明,细胞外囊泡(EVs)是神经退行性疾病的介质和生物标志物。已知阿尔茨海默病(AD)有两种不同形式:晚发性散发性形式(SAD)和早发性家族性形式(FAD)。最近,神经血管功能障碍和全身免疫成分改变与AD神经退行性变有关。因此,我们对死后SAD和FAD患者的全身EVs进行了表征,并评估了它们对神经胶质细胞和内皮细胞的影响。我们发现SAD患者血管腔外部分的CLN - 5斑点增加,具有囊泡形态。两种形式的AD都与更大、数量更多的全身EVs相关。具体而言,SAD患者含有线粒体的内皮细胞和白细胞衍生的EVs增加;相比之下,FAD患者血小板衍生的EVs增加。我们检测到与凝血级联、炎症和脂质 - 碳水化合物代谢相关的SAD - EVs和FAD - EVs的蛋白质组成存在差异。使用单培养和共培养(内皮细胞 - 星形胶质细胞 - 神经元)以及人类皮质类器官,我们表明AD - EVs诱导细胞毒性。两种形式的AD都表现为神经元分支面积减少和星形胶质细胞反应性增强,但SAD - EVs比FAD - EVs对内皮细胞的有害影响更大。此外,FAD - EVs和SAD - EVs在皮质类器官模型中影响钙动力学。我们的研究结果表明,全身AD - EVs的表型由疾病的病因病理(SAD或FAD)差异定义,这导致神经退行性变中涉及的神经血管单元(NVU)细胞发生差异改变。